GCA Altium advises Cheplapharm on raising a EUR 300m incremental TLB facility
GCA Altium acted as exclusive debt advisor to Cheplapharm Arzneimittel GmbH on its successful increase of the syndicated and rated TLB facilities.
Cheplapharm is a family-owned pharmaceutical company offering branded off-patent specialty products. The group has a unique international footprint and a broad portfolio of over 80 products across 10+ therapeutic areas and focuses on acquiring original well established off-patent niche and legacy branded pharmaceuticals from large pharmaceutical companies, creating value through its global footprint.
Earlier this year, GCA Altium advised Cheplapharm on its debut on the syndicated and rated TLB market. Following several acquisitions during the summer resulting in strong growth of Cheplapharm, the TLB facilities were increased by EUR 300m to provide liquidity for further M&A projects.
Sebastian F. Braun, CEO of Cheplapharm commented: „With the acquisition of five products in August and September, we are continuing our growth path and envisage to sign one more deal this year. The incremental facility provides us with the necessary liquidity.”
Johannes Schmittat, Managing Director at GCA Altium added: “We have been able to use the positive momentum of the institutional loan markets to provide Cheplapharm with very attractive terms on the incremental facility. Institutional investors have shown strong appetite in lending to Cheplapharm.”